SevenBridge Financial Group LLC lifted its stake in shares of Celgene Co. (NASDAQ:CELG) by 32.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 820 shares of the biopharmaceutical company’s stock after acquiring an additional 201 shares during the period. SevenBridge Financial Group LLC’s holdings in Celgene were worth $76,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Management Corp VA acquired a new stake in shares of Celgene during the first quarter valued at $10,955,000. Canyon Capital Advisors LLC purchased a new position in Celgene during the first quarter worth about $119,226,000. Tibra Equities Europe Ltd purchased a new position in Celgene during the first quarter worth about $6,396,000. Ruffer LLP purchased a new position in Celgene during the first quarter worth about $226,613,000. Finally, Global Trust Asset Management LLC lifted its position in Celgene by 212.3% during the first quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock worth $430,000 after buying an additional 3,098 shares during the period. 74.84% of the stock is currently owned by institutional investors and hedge funds.
CELG has been the topic of several recent analyst reports. Mizuho reiterated a “buy” rating and set a $103.00 target price on shares of Celgene in a research report on Wednesday, July 3rd. Cowen reiterated a “hold” rating and set a $102.00 target price on shares of Celgene in a research report on Tuesday. Barclays downgraded Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research report on Friday, May 3rd. ValuEngine downgraded Celgene from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price on the stock in a research report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $94.81.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.17. The company had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.22 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same period last year, the business posted $2.16 EPS. On average, equities analysts predict that Celgene Co. will post 9.85 earnings per share for the current fiscal year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What is the formula for the cash asset ratio?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.